Limits...
Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure.

Quaranta L, Riva I, Katsanos A, Floriani I, Centofanti M, Konstas AG - Clin Ophthalmol (2015)

Bottom Line: Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle.When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues.Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease.

View Article: PubMed Central - PubMed

Affiliation: Centre for the Study of Glaucoma, University of Brescia, Brescia, Italy.

ABSTRACT
Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular meshwork. Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues. The fixed combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to the concomitant administration of the two drugs. Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP.

No MeSH data available.


Related in: MedlinePlus

Travoprost chemical structure.Notes: (A) Travoprost prodrug. (B) Travoprost free acid, after hydrolysis of isopropyl ester in carbon-1 position.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4401333&req=5

f1-opth-9-633: Travoprost chemical structure.Notes: (A) Travoprost prodrug. (B) Travoprost free acid, after hydrolysis of isopropyl ester in carbon-1 position.

Mentions: Travoprost is a synthetic derivative of naturally occurring PG F2α (PGF2α). Natural PGs, especially of the F series, are relatively polar and hydrophilic, and poorly penetrate cell membranes.16 Synthetic esterification in carbon-1 position gives travoprost lipophilic properties, increasing penetration though lipid membranes such as corneal epithelium.17,18 During the corneal passage, travoprost isopropyl ester situated in carbon-1 position is hydrolyzed, generating an active free acid (Figure 1).14,15,19


Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure.

Quaranta L, Riva I, Katsanos A, Floriani I, Centofanti M, Konstas AG - Clin Ophthalmol (2015)

Travoprost chemical structure.Notes: (A) Travoprost prodrug. (B) Travoprost free acid, after hydrolysis of isopropyl ester in carbon-1 position.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4401333&req=5

f1-opth-9-633: Travoprost chemical structure.Notes: (A) Travoprost prodrug. (B) Travoprost free acid, after hydrolysis of isopropyl ester in carbon-1 position.
Mentions: Travoprost is a synthetic derivative of naturally occurring PG F2α (PGF2α). Natural PGs, especially of the F series, are relatively polar and hydrophilic, and poorly penetrate cell membranes.16 Synthetic esterification in carbon-1 position gives travoprost lipophilic properties, increasing penetration though lipid membranes such as corneal epithelium.17,18 During the corneal passage, travoprost isopropyl ester situated in carbon-1 position is hydrolyzed, generating an active free acid (Figure 1).14,15,19

Bottom Line: Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle.When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues.Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease.

View Article: PubMed Central - PubMed

Affiliation: Centre for the Study of Glaucoma, University of Brescia, Brescia, Italy.

ABSTRACT
Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular meshwork. Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues. The fixed combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to the concomitant administration of the two drugs. Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP.

No MeSH data available.


Related in: MedlinePlus